New Classifications of Five Distinct “Sleep” Profi... ...
A Professional Overview of Hypertension ...
High-speed imaging tracks live brain cell activity...
Drug candidate slows motor neuron disease progress...
Drug candidate slows motor neuron disease progress...
Mark Cuban: A Master Disrupter for American Health...
Superbugs on your plate: How antimicrobial resistance spread...
June 13,2026
Can marijuana cause lung cancer?...
June 12,2026
Standard depression screening could be missing key symptoms ...
June 11,2026
More women are having babies later in life. How to improve y...
June 10,2026
For severe babesiosis, red blood cell exchange is associated...
June 09,2026
Cause or effect? Study answers question about gene linked wi...
June 08,2026
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
Eye Infections (Updated) | Clinical Medicine...
Announcement of the 2025 Nobel Prize in ...
Dr. Fauci among hundreds who've contract...
Why are young, healthy adults experienci...
Reprogramming Stem Cells Could Cure Type...
More News
Microbial signature of colorectal cancer-associated mutations identified

Microbial signature of colorectal cancer-associated mutations identified

by American Society for MicrobiologyCredit: CC0 Public DomainFor about 40% of people diagnosed with colorectal cancer (CRC), the tumor carries a mutation in a gene called KRAS. Many of those muta
Oncology April 06,2024
Microbial signature of colorectal cancer-associated mutations identified

Microbial signature of colorectal cancer-associated mutations identified

by American Society for MicrobiologyCredit: CC0 Public DomainFor about 40% of people diagnosed with colorectal cancer (CRC), the tumor carries a mutation in a gene called KRAS. Many of those muta
Oncology April 06,2024
Five-year interval is safe for prostate cancer screening, research shows

Five-year interval is safe for prostate cancer screening, research shows

by European Association of UrologyCredit: CC0 Public DomainA simple blood test every five years is sufficient to screen low risk men for prostate cancer, new research has shown.The PSA blood test
Oncology April 06,2024
Five-year interval is safe for prostate cancer screening, research shows

Five-year interval is safe for prostate cancer screening, research shows

by European Association of UrologyCredit: CC0 Public DomainA simple blood test every five years is sufficient to screen low risk men for prostate cancer, new research has shown.The PSA blood test
Oncology April 06,2024
Soluble immune checkpoint factors in blood as potential biomarkers of therapeutic efficacy for ICI cancer immunotherapy

Soluble immune checkpoint factors in blood as potential biomarkers of therapeutic efficacy for ICI cancer immunotherapy

by Kindai UniversityThe concentration of soluble PD-L1m PD-1, CTLA4 in plasma were highly correlated with the expression of genes associated with exhaustion in the peripheral CD8+T cells. R valu
Oncology April 06,2024
Soluble immune checkpoint factors in blood as potential biomarkers of therapeutic efficacy for ICI cancer immunotherapy

Soluble immune checkpoint factors in blood as potential biomarkers of therapeutic efficacy for ICI cancer immunotherapy

by Kindai UniversityThe concentration of soluble PD-L1m PD-1, CTLA4 in plasma were highly correlated with the expression of genes associated with exhaustion in the peripheral CD8+T cells. R valu
Oncology April 06,2024
Fighting pancreatic cancer with computers and lasers

Fighting pancreatic cancer with computers and lasers

by Anthony King,Horizon: The EU Research & Innovation MagazinePancreatic cancer cells (blue) growing as a sphere encased in membranes (red). Credit: National Cancer InstituteFaster detection
Oncology April 06,2024
Fighting pancreatic cancer with computers and lasers

Fighting pancreatic cancer with computers and lasers

by Anthony King,Horizon: The EU Research & Innovation MagazinePancreatic cancer cells (blue) growing as a sphere encased in membranes (red). Credit: National Cancer InstituteFaster detection
Oncology April 06,2024
A new hope in immunotherapy against cancer

A new hope in immunotherapy against cancer

by Karolinska InstitutetIdentification of SB02024 as a potent and selective inhibitor of VPS34. (A) Chemical structure of SB02024. (B) Cartoon representation of the structure of complex between V
Oncology April 06,2024
A new hope in immunotherapy against cancer

A new hope in immunotherapy against cancer

by Karolinska InstitutetIdentification of SB02024 as a potent and selective inhibitor of VPS34. (A) Chemical structure of SB02024. (B) Cartoon representation of the structure of complex between V
Oncology April 06,2024
New insights into how tumors on adrenal glands develop

New insights into how tumors on adrenal glands develop

by Kyushu UniversitySteroids-producing nodules, or SPNs, exhibit a two-layered zona fasciculata (zF) and zona reticularis (zR) like structure, where two distinct cell populations might contribute
Oncology April 06,2024
New insights into how tumors on adrenal glands develop

New insights into how tumors on adrenal glands develop

by Kyushu UniversitySteroids-producing nodules, or SPNs, exhibit a two-layered zona fasciculata (zF) and zona reticularis (zR) like structure, where two distinct cell populations might contribute
Oncology April 06,2024
New study targets major risk factor for gastric cancer

New study targets major risk factor for gastric cancer

by University of Miami Leonard M. Miller School of MedicineCredit: CC0 Public DomainWhat if we could eliminate a major risk factor for stomach cancer in Black, Asian, Latino and other vulnerable
Oncology April 06,2024
New study targets major risk factor for gastric cancer

New study targets major risk factor for gastric cancer

by University of Miami Leonard M. Miller School of MedicineCredit: CC0 Public DomainWhat if we could eliminate a major risk factor for stomach cancer in Black, Asian, Latino and other vulnerable
Oncology April 06,2024
New insights into aggressive breast cancer and potential treatment options

New insights into aggressive breast cancer and potential treatment options

by Marianne Lie Becker,University of Southern DenmarkThe findings made in the recent research projects. Credit: Professor Vijay Tiwari, University of Southern DenmarkTriple-negative breast cance
Oncology April 06,2024
New insights into aggressive breast cancer and potential treatment options

New insights into aggressive breast cancer and potential treatment options

by Marianne Lie Becker,University of Southern DenmarkThe findings made in the recent research projects. Credit: Professor Vijay Tiwari, University of Southern DenmarkTriple-negative breast cance
Oncology April 06,2024
Study shows 'feasibility' of ending specialist follow-up in patients with low-risk chronic lymphocytic leukemia

Study shows 'feasibility' of ending specialist follow-up in patients with low-risk chronic lymphocytic leukemia

by American Society of HematologyCredit: CC0 Public DomainA study published inBlood Advancesshowed that among patients in Denmark who had slow-growing chronic lymphocytic leukemia (CL
Oncology April 06,2024
Study shows 'feasibility' of ending specialist follow-up in patients with low-risk chronic lymphocytic leukemia

Study shows 'feasibility' of ending specialist follow-up in patients with low-risk chronic lymphocytic leukemia

by American Society of HematologyCredit: CC0 Public DomainA study published inBlood Advancesshowed that among patients in Denmark who had slow-growing chronic lymphocytic leukemia (CL
Oncology April 06,2024
Second primary malignancy risk increased after cutaneous B-cell lymphoma

Second primary malignancy risk increased after cutaneous B-cell lymphoma

by Elana GotkinePatients with primary cutaneous B-cell lymphomas (PCBCLs) have an increased risk for second primary malignancies (SPMs), according to a studypublishedonline March 19 in the
Oncology April 06,2024
Second primary malignancy risk increased after cutaneous B-cell lymphoma

Second primary malignancy risk increased after cutaneous B-cell lymphoma

by Elana GotkinePatients with primary cutaneous B-cell lymphomas (PCBCLs) have an increased risk for second primary malignancies (SPMs), according to a studypublishedonline March 19 in the
Oncology April 06,2024
More News
Week’s Top
Podcasts
... Preparing for a tough exam? A tough gym workout could help with your studies ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... Brain activity goes to extremes in soccer fans, neuroimaging reveals ...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com